文献速递慢性肾脏病肾小球疾病

APOL1肾脏风险变异与蛋白质组学

APOL1 Kidney Risk Variants and Proteomics.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-04-26

在461名AASK参与者中评估APOL1风险变异与6790种血清蛋白的关联,并在875名ARIC黑人参与者中重复验证。两个风险等位基因与APOL1、APOL2、CLSTN2、MMP-2、SPOCK2和TIMP-2蛋白血清水平降低相关,但未发现这些蛋白介导APOL1相关的肾衰竭风险,APOL1蛋白水平与肾衰竭无关联。

要点

  • 两个APOL1风险等位基因与血清APOL1、APOL2、CLSTN2、MMP-2、SPOCK2和TIMP-2水平降低相关。
  • APOL1高风险状态与肾衰竭风险增加1.6倍相关,但所识别的蛋白均未介导该关联。
  • APOL1蛋白水平与肾衰竭无关联。

核心结论

  • APOL1风险变异与APOL1及其他蛋白的循环水平降低强烈相关,但无一介导APOL1相关的肾衰竭风险,APOL1蛋白水平亦与肾衰竭无关联。

研究设计与样本

  • 在461名非裔美国人肾脏病与高血压研究(AASK)参与者中(平均年龄54岁,女性41%,平均GFR 46 ml/min per 1.73 m2),采用线性回归模型评估APOL1风险变异与6790种血清蛋白(通过SOMAscan测量)的关联,协变量包括年龄、性别、欧洲血统百分比和蛋白主成分1-5。
  • 在875名动脉粥样硬化风险社区(ARIC)研究黑人参与者中(平均年龄75岁,女性66%,平均eGFR 67 ml/min per 1.73 m2)重复验证。

主要发现

  • 在AASK研究中,携带两个( vs 零个或一个)APOL1风险等位基因与血清APOL1水平降低相关(P=3.11E-13;P=3.12E-06[两个适配体])。
  • 在AASK研究中,携带两个( vs 零个或一个)APOL1风险等位基因与血清APOL2(P=1.45E-10)、CLSTN2(P=2.66E-06)、MMP-2(P=2.96E-06)、SPOCK2(P=2.57E-05)和TIMP-2(P=2.98E-05)蛋白水平降低相关。
  • 在ARIC研究中,APOL1风险等位基因与APOL1相关(P=1.28E-11);MMP-2(P=0.004)和TIMP-2(P=0.007)仅在加性模型中相关,APOL2不可用。
  • 在AASK研究中,APOL1高风险状态与肾衰竭风险增加1.6倍相关;所识别的蛋白均未介导该关联。
  • 在两个队列中,APOL1蛋白水平均与肾衰竭无关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The APOL1 risk variants (G1 and G2) are associated with kidney disease among Black adults, but the clinical presentation is heterogeneous. In mouse models and cell systems, increased gene expression of G1 and G2 confers cytotoxicity. How APOL1 risk variants relate to the circulating proteome warrants further investigation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 461 African American Study of Kidney Disease and Hypertension (AASK) participants (mean age: 54 years; 41% women; mean GFR: 46 ml/min per 1.73 m2), we evaluated associations of APOL1 risk variants with 6790 serum proteins (measured via SOMAscan) using linear regression models. Covariates included age, sex, percentage of European ancestry, and protein principal components 1-5. Associated proteins were then evaluated as mediators of APOL1-associated risk for kidney failure. Findings were replicated among 875 Atherosclerosis Risk in Communities (ARIC) study Black participants (mean age: 75 years; 66% women; mean eGFR: 67 ml/min per 1.73 m2). RESULTS: In the AASK study, having two (versus zero or one) APOL1 risk alleles was associated with lower serum levels of APOL1 (P=3.11E-13; P=3.12E-06 [two aptamers]), APOL2 (P=1.45E-10), CLSTN2 (P=2.66E-06), MMP-2 (P=2.96E-06), SPOCK2 (P=2.57E-05), and TIMP-2 (P=2.98E-05) proteins. In the ARIC study, APOL1 risk alleles were associated with APOL1 (P=1.28E-11); MMP-2 (P=0.004) and TIMP-2 (P=0.007) were associated only in an additive model, and APOL2 was not available. APOL1 high-risk status was associated with a 1.6-fold greater risk of kidney failure in the AASK study; none of the identified proteins mediated this association. APOL1 protein levels were not associated with kidney failure in either cohort. CONCLUSIONS: APOL1 risk variants were strongly associated with lower circulating levels of APOL1 and other proteins, but none mediated the APOL1-associated risk for kidney failure. APOL1 protein level was also not associated with kidney failure.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Chen TK, Surapaneni AL, Arking DE, et al. APOL1 Kidney Risk Variants and Proteomics. Clin J Am Soc Nephrol. 2022. PMID: 35474272. doi:10.2215/CJN.14701121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。